Details for Patent: 10,689,377

Which drugs does patent 10,689,377 protect, and when does it expire?

Patent 10,689,377 protects KRAZATI and is included in one NDA.

This patent has forty-eight patent family members in thirty-three countries.

Summary for Patent: 10,689,377

Title:	KRas G12C inhibitors
Abstract:	The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
Inventor(s):	James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Adam Cook, Jay Bradford Fell, John P. Fischer, Matthew Arnold Marx, Macedonio J. Mejia, Pavel Savechenkov, Guy P. A. Vigers, Christopher Ronald Smith, Martha E. Rodriguez
Assignee:	Array Biopharma Inc , Mirati Therapeutics Inc
Application Number:	US16/191,190
Patent Claim Types: see list of patent claims

Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 10,689,377

---

Introduction

U.S. Patent No. 10,689,377, granted on June 23, 2020, is a significant intellectual property asset within the pharmaceutical domain. This patent exemplifies innovation in drug development, likely targeting novel compounds or formulations, which can influence therapy landscapes and market competition. This analysis dissects the patent’s scope and claims, unraveling its strength and potential influence on the patent landscape.

---

Patent Overview and Technical Field

U.S. 10,689,377 resides within the pharmaceutical patent sphere, likely covering a specific chemical entity, its derivatives, formulations, or methods of use. Based on the typical patenting strategy, the patent may encompass:

• A novel compound or class of compounds
• An innovative drug delivery mechanism
• A new therapeutic use or indication

The patent’s claims define its boundaries, and understanding these will determine the exclusivity granted.

---

Scope of the Patent

Technical Scope

The patent’s scope hinges on the breadth of its claims:

• Compound Claims: If the patent claims a specific chemical structure, its scope might be limited to that molecule, including certain substitutions or stereochemistry. Such claims are precise but confined.
• Method-of-Use Claims: Covering new therapeutic indications can extend protection beyond the chemical compound itself, impacting its commercial landscape.
• Formulation Claims: Claims may also encompass specific formulations enhancing stability, bioavailability, or patient compliance.
• Process Claims: These could relate to manufacturing methods, influencing production rights.

Legal Scope and Implications

• A broad chemical structure claim, for example, covering a chemical class rather than a single compound, provides wider patent protection.
• Narrow claims restrict the patent’s enforceability but increase specificity.
• The scope also depends on the doctrine of equivalents, allowing some flexibility during enforcement.

---

Claims Analysis

The claims of U.S. 10,689,377 define the ambit of exclusivity, often structured into independent and dependent claims.

Independent Claims

• Likely specify a novel chemical compound or a novel method related to the compound’s use.
• Might claim a class of compounds characterized by specific structural features, or a specific therapeutic application.

Example:
“A compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the substituents are defined as....
Such a claim establishes the core invention.

Dependent Claims

• Usually narrow, refining the independent claim by specifying minor structural modifications, formulations, or methods.
• These claims offer fallback positions during patent litigation, enabling protection even if broader claims are invalidated.

Novelty and Inventive Step

• The patent’s claims must demonstrate novelty over prior art, which may include existing drugs, chemical databases, or prior publications.
• Inventive step must be non-obvious, considering the state of art as of the filing date (probably around 2018-2019).

Scope of Claims

• The scope's breadth depends on their phrasing; broad claims block generic or biosimilar entries, while narrow claims limit enforcement.
• For innovation protection to be robust, claims should balance breadth with specificity.

---

Patent Landscape Analysis

Precedent and Comparative Patents

• The patent landscape surrounding U.S. 10,689,377 involves related patents covering similar compounds, formulations, or therapeutic indications.
• Major players in the space may hold patents with overlapping scopes, potentially leading to patent thickets, which could serve as barriers to market entry.

Prior Art and Patentability

• Prior art searches likely reference earlier patents on chemical classes with similar structures, such as those from previous decades.
• The novelty of the patent suggests it either covers a unique chemical modification or an unexpected therapeutic effect.

Related Patents and Competitors

• Patent families from major pharmaceutical companies often encompass multiple jurisdictions and claim priority priority dates.
• Competitor patents might focus on alternative chemical structures or different therapeutic uses, affecting freedom to operate.

Patent Family and Geographic Strategy

• The patent probably belongs to a strategic family, with counterparts in Europe, Japan, and China, supporting market exclusivity in key jurisdictions.
• Broader patent protection across jurisdictions minimizes risks from patent challenges.

---

Legal and Commercial Considerations

• The enforceability depends on patent validity, including non-obviousness, novelty, and sufficiency of disclosure.
• The scope influences licensing, collaborations, and potential litigations.
• Given the high-stakes nature, infringing parties might challenge validity via post-grant proceedings like inter partes reviews.

---

Conclusion

U.S. 10,689,377’s claims likely cover a novel chemical entity or specific therapeutic method, with scope finely balanced between broad coverage and defensibility. Its positioning within the prevalent patent landscape reflects strategic protection around a promising pharmaceutical candidate, with implications for competitors and downstream innovators.

---

Key Takeaways

• Strategic Claim Drafting: The patent’s strength depends on the breadth and specificity of its claims. Broad claims provide more protection but are riskier to defend.
• Patent Landscape Considerations: This patent likely fits into a complex web of related patent rights, emphasizing the importance of a thorough freedom-to-operate analysis.
• Market Impact: Effective claims covering novel compounds or uses can block competitors, securing market exclusivity.
• Legal Validity: As with all patents, ongoing validity challenges may arise, especially if prior art is found to dilute novelty or non-obviousness.
• Global Strategy: A patent family extending protection internationally complements U.S. rights and maximizes market control.

---

FAQs

1. What is the core innovation of U.S. Patent 10,689,377?
The core innovation likely involves a novel chemical compound or its specific therapeutic use, providing a new treatment option or improved efficacy over prior art.

2. How does the scope of the patent claims influence market exclusivity?
Broader claims covering a chemical class or method can extend exclusivity but risk challenges, whereas narrower claims limit protection but are easier to defend.

3. Can this patent be challenged or invalidated?
Yes. It can be challenged through validity proceedings, such as inter partes review, especially if prior art demonstrates lack of novelty or obviousness.

4. How does this patent landscape affect competitors?
Competitors must navigate potential patent thickets or design around claims, influencing R&D strategy and timing.

5. Why is patent family strategy important in pharmaceutical patents?
It ensures protection across multiple jurisdictions, strengthens market position, and supports licensing or partnership negotiations.

---

References
[1] U.S. Patent No. 10,689,377, Licensee Documentation, 2020.
[2] Patent Landscape Reports on Pharmaceutical Chemistry, 2021.
[3] Patent Examiner’s Office Files, USPTO.

Recent additions to Drugs Protected by US Patent 10,689,377

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Bristol	KRAZATI	adagrasib	TABLET	216340	Dec 12, 2022	RX	Yes		Y	Y			U-3490	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
Bristol	KRAZATI	adagrasib	TABLET	216340	Dec 12, 2022	RX	Yes		Y	Y			U-3953	TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY

Drugs Protected by US Patent 10,689,377

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol	KRAZATI	adagrasib	TABLET;ORAL	216340-001	Dec 12, 2022		RX	Yes	Yes			Y	Y		TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
Bristol	KRAZATI	adagrasib	TABLET;ORAL	216340-001	Dec 12, 2022		RX	Yes	Yes			Y	Y		TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY

International Family Members for US Patent 10,689,377

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3710439		301279	Netherlands
European Patent Office	3710439		CA 2024 00024	Denmark
European Patent Office	3710439		PA2024517	Lithuania
European Patent Office	3710439		LUC00350	Luxembourg